- Home
- RENB vs OVID Comparison
RENB vs OVID Comparison
Compare RENB & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- OVID
- Stock Information
- Founded
- RENB 2011
- OVID 2014
- Country
- RENB United States
- OVID United States
- Employees
- RENB N/A
- OVID N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- OVID Health Care
- Exchange
- RENB Nasdaq
- OVID Nasdaq
- Market Cap
- RENB 101.3M
- OVID 85.2M
- IPO Year
- RENB N/A
- OVID 2017
- Fundamental
- Price
- RENB $0.50
- OVID $1.06
- Analyst Decision
- RENB
- OVID Strong Buy
- Analyst Count
- RENB 0
- OVID 5
- Target Price
- RENB N/A
- OVID $4.04
- AVG Volume (30 Days)
- RENB 298.6K
- OVID 248.3K
- Earning Date
- RENB 11-14-2024
- OVID 11-12-2024
- Dividend Yield
- RENB N/A
- OVID N/A
- EPS Growth
- RENB N/A
- OVID N/A
- EPS
- RENB N/A
- OVID N/A
- Revenue
- RENB N/A
- OVID $631,695.00
- Revenue This Year
- RENB N/A
- OVID $21.51
- Revenue Next Year
- RENB N/A
- OVID $7,300.79
- P/E Ratio
- RENB N/A
- OVID N/A
- Revenue Growth
- RENB N/A
- OVID 113.21
- 52 Week Low
- RENB $0.40
- OVID $0.68
- 52 Week High
- RENB $5.25
- OVID $4.10
- Technical
- Relative Strength Index (RSI)
- RENB 44.10
- OVID 34.14
- Support Level
- RENB $0.46
- OVID $0.99
- Resistance Level
- RENB $0.56
- OVID $1.47
- Average True Range (ATR)
- RENB 0.08
- OVID 0.11
- MACD
- RENB -0.01
- OVID -0.03
- Stochastic Oscillator
- RENB 18.72
- OVID 4.56
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.